Gongwin Biopharm Holdings Co., Ltd. (TPEX: 6617)
120.00
-6.00 (-4.76%)
Sep 10, 2024, 1:30 PM CST
Gongwin Biopharm Holdings Company Description
Gongwin Biopharm Holdings Co., Ltd., a clinical-stage biopharmaceutical company, develops anticancer drugs.
It is developing PTS302, which has completed Phase III clinical trials for the treatment of lung cancer; PTS100, which is in Phase II clinical trials for the treatment of liver cancer; PTS-02 for the treatment of adenoid cystic carcinoma; and PTS500 for the treatment of malignant pleural effusion.
The company was founded in 2014 and is based in Taipei, Taiwan.
Gongwin Biopharm Holdings Co., Ltd.
Country | Cayman Islands |
Founded | 2014 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Mao Yuan Lin |
Contact Details
Address: No. 80, Jianguo North Road Taipei, 104 Taiwan | |
Phone | 886 2 2503 5282 |
Website | gongwinbiopharm.com |
Stock Details
Ticker Symbol | 6617 |
Exchange | Taipei Exchange |
Fiscal Year | January - December |
Reporting Currency | TWD |
SIC Code | 2836 |
Key Executives
Name | Position |
---|---|
Lester Wu Ph.D. | Founder and Chairman |
Mao Yuan Lin | GM and Director |
Rocky Shih | Co-Founder |
Nan Hu Wei | Chief Financial Officer and Head of Administration Division |